In nasal cavity and paranasal sinus cancers, p16-positive OPC, and p16-negative oropharyngeal and hypopharyngeal and laryngeal cancers, the SLFN11-positive groups exhibited a significantly superior PFS compared to the SLFN11-negative groups (5-year PFS: 71.2% vs. 34.9%, respectively, p = 0.002, Figure 2B; 5-year PFS: 91.7% vs. 62.5%, respectively, p = 0.023, Figure 2C; 5-year PFS: 76.7% vs. 57.7%, respectively, p = 0.014, Figure 2D). This evidence concerns the gene SLFN11 and paranasal sinus cancer.